BCMA/CD19 dual-targeting with FasTCAR: AZD0120 demonstrates potent preclinical efficacy in multiple myeloma
Huan Shi, Wenjie Yin, Hua Zhang, Xiaoyan Jiang, Jiaping He, Guangyao Zhu, Michael Glen Overstreet, Mark Cobbold, Lianjun Shen
This paper evaluates AZD0120, a dual-targeting BCMA/CD19 CAR-T therapy, showing improved preclinical efficacy and tumor control in multiple myeloma models.
bioRxiv · Jun 9, 2026 · PreprintCancer Biology